Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CARL ZEISS MEDITEC AG

(AFX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Carl Zeiss Meditec : ZEISS Introduces a Series of Major Innovations and Industry-First Software Applications as Part of the ZEISS Medical Ecosystem

09/20/2021 | 12:12pm EDT

ZEISS introduces a new integrated cataract workflow solution for lens replacement with the launch of the
ZEISS QUATERA 700*. This revolution in phaco technology includes the ZEISS patented QUATTRO Pump® which delivers chamber stability independent of intra-ocular pressure (IOP) and flow. The QUATERA 700 increases a surgeon's workflow efficiency from the clinic to the operating room, enabling one digitally integrated surgical workflow. "I have been looking forward to having this system in my OR, it was a big moment for me," said Sri Ganesh, MD, Chairman and Managing Director of Nethradhama Super Speciality Eye Hospital, Bangalore/India. "Then I saw that it actually works - the chamber is so stable, the new pump works very well. It is something that I've never seen before and I've used all different phaco machines in my career of almost three decades."

The ZEISS Cataract Workflow is further enhanced with two new and original surgical software applications. The new ZEISS EYEGUIDE*patient software application is a virtual coach for patients and clinics to stay connected through the entire cataract treatment process. The ZEISS Surgery Optimizer*application is developed for surgeons as a new and innovative way of utilizing surgical videos to enable self-training of physicians and standardization of surgical techniques.

Additionally, the new ZEISS CT LUCIA 621* monofocal IOL features the patented ZEISS Optic (ZO) Asphericity Concept with its uniquely forgiving design to deliver excellent visual outcomes for a broad range of patients and surgical situations, and the new ZEISS OPTIKIT* offers a fully customizable surgical pack that perfectly complements the ZEISS Lens Extraction offering.

"Together with ZEISS' data platform and surgical planning software, these innovations position ZEISS as a full surgical leader in ophthalmology," said Euan S. Thomson, PhD, President of Ophthalmic Devices and Head of the Digital Business Unit for Carl Zeiss Meditec. "Harnessing the power of data-generated insights ZEISS creates an environment where connectivity, automation, artificial intelligence, and safe and efficient management of data can solve the challenges that customers face every day."

The new ZEISS VISUMAX 800*, the next generation of ZEISS femtosecond lasers, creates a comfortable patient and surgeon experience by reducing laser time and potential transcription errors with easy treatment planning and data analysis via FORUM® to the ZEISS Refractive Workplace* through a digitally connected corneal refractive workflow.

"I am sure every surgeon will appreciate the benefits that come with the digital connectivity such as elimination of transcription errors and the possibility of remote planning, but really the greatest step forward is the incredible speed of the VISUMAX 800 laser scanning making suction loss virtually a thing of the past," said Prof. Dr. Walter Sekundo, Professor and Chairman, Ophthalmology Department, Philipps University of Marburg, Germany.

Additionally, the ZEISS Retina Workflow has been enhanced beyond the traditional ophthalmology office and into primary healthcare settings with the new ZEISS VELARA Teleretinal Screening System, a complete end-to-end solution used by primary care providers to help increase the quality and compliance of diabetic patients, allowing annual retinal exams to be completed during routine primary care visits. The solution is available only in the U.S. initially.

"We always think of ourselves as providing the best medical care available. And so how can we do that in the shortest time possible, how can we get patients in and out?" said Dr. Nathan Kiskila, Urgent Care General Practitioner President, Founder and Co-Owner of Marque Medical, California/USA. "The ZEISS VELARA Teleretinal Screening System is one more thing that I think we will have in our toolbox as physicians to offer to our patients to really provide good medical care and make things happen."

The new integrated devices, software applications and other workflow solutions will be showcased this week during the ZEISS Innovation Week from September 21 to 23, 2021. For more information, visit www.zeiss.com/med.

Disclaimer

Carl Zeiss Meditec AG published this content on 20 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 September 2021 16:11:04 UTC.


ę Publicnow 2021
All news about CARL ZEISS MEDITEC AG
10/19JENOPTIK AG : Jenoptik strengthens global photonics business with the acquisition of Berli..
DJ
09/30CARL ZEISS MEDITEC : Appoints New CEO
MT
09/30Carl Zeiss Meditec AG Announces Management Changes
CI
09/30CARL ZEISS MEDITEC : Change to Executive Board of Carl Zeiss Meditec AG
PU
09/30CARL ZEISS MEDITEC : Change to Executive Board of Carl Zeiss Meditec AG
EQ
09/30PRESS RELEASE : Change to Executive Board of Carl Zeiss Meditec AG
DJ
09/30Carl Zeiss Meditec AG Announces Executive Changes
CI
09/30Leadership Change in the Executive Board of Carl Zeiss Meditec AG
DJ
09/22JENOPTIK AG : Release according to -3-
DJ
09/22JENOPTIK AG : Release according to Article 40, Section 1 of the WpHG [the German Securitie..
DJ
More news
Analyst Recommendations on CARL ZEISS MEDITEC AG
More recommendations
Financials
Sales 2021 1 653 M 1 918 M 1 918 M
Net income 2021 254 M 294 M 294 M
Net cash 2021 687 M 798 M 798 M
P/E ratio 2021 60,9x
Yield 2021 0,47%
Capitalization 15 460 M 17 924 M 17 938 M
EV / Sales 2021 8,94x
EV / Sales 2022 8,04x
Nbr of Employees 3 371
Free-Float 40,9%
Chart CARL ZEISS MEDITEC AG
Duration : Period :
Carl Zeiss Meditec AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARL ZEISS MEDITEC AG
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Last Close Price 172,85 €
Average target price 165,40 €
Spread / Average Target -4,31%
EPS Revisions
Managers and Directors
Ludwin Monz President & Chief Executive Officer
Justus Felix Wehmer Chief Financial Officer
Michael Kaschke Chairman-Supervisory Board
Markus Guthoff Member-Supervisory Board
Christian MŘller Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
CARL ZEISS MEDITEC AG58.72%17 924
THERMO FISHER SCIENTIFIC30.48%239 332
DANAHER CORPORATION37.80%219 325
INTUITIVE SURGICAL, INC.27.87%124 568
SIEMENS HEALTHINEERS AG42.35%77 688
EDWARDS LIFESCIENCES CORPORATION28.58%72 923